Serious Cardiopulmonary Reactions

Perflutren Lipid Microsphere (Definity)

• Serious cardioplumonary reactions, including fatalities have occurred uncommonly during or following perflutren containing microsphere administration. Most serious reactions occur within 30 minutes of administration.
• Assess all patients for the presence of any condition that precludes administration of Perflutren Lipid Microsphere (Definity)  (See CONTRAINDICATIONS)
• Always have resuscitation equipment and trained personnel readily available (See WARNINGS) .

Perflutren Protein-Type A Microspheres (Optison)

• Serious cardioplumonary reactions, including fatalities have occurred during or following perflutren containing microsphere administration.
• Assess all patients for the presence of any condition that precludes administration of Perflutren Protein-Type A Microspheres (Optison). 
• In patients with pulmonary hypertension or unstable cardiopulmonary conditions, monitor patients during and for at least 30 minutes following administration, including vital signs, electrocardiography and cutaneous oxygen saturation. 
• Always have resuscitation equipment and trained personnel readily available .